XORTX Therapeutics Completes Successful Private Placement
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has achieved a significant milestone by successfully completing a non-brokered private placement. The company raised a total of USD $114,500 through the issuance of 156,849 units, priced at USD $0.73 per unit. This funding is crucial for advancing the company’s innovative therapies aimed at treating gout and progressive kidney disease.
Details of the Private Placement Offering
Each unit in this placement consists of one common share and one common share purchase warrant. Notably, each warrant allows the holder to purchase an additional common share at USD $1.20 for a period of 60 months following issuance. However, if the closing price of the common shares exceeds USD $2.00 for ten consecutive trading days, the warrants will be accelerated and will expire 30 business days thereafter, a strategic move that provides flexibility and leeway for investors.
Utilization of Proceeds
The funds raised through this offering will support XORTX’s gout programs and provide general corporate and working capital. This financial boost will aid in the ongoing development of the company's leading drug candidates, which aim to improve the quality of life for those suffering from gout and other related kidney diseases.
Compliance and Regulatory Details
The completion of this offering was conditionally approved by the TSX Venture Exchange (TSXV). The securities issued as part of this offering will be subject to a four-month and one-day statutory hold period, ensuring compliance with regulatory requirements and facilitating market stability.
About XORTX Therapeutics Inc.
XORTX Therapeutics is a growing pharmaceutical company recognized for its innovative approaches to treating various kidney-related conditions. The company is advancing several clinically advanced therapies, including XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injuries related to respiratory virus infections. Additionally, the company is in the pre-clinical stage of development for XRx-225, targeting Type 2 diabetic nephropathy. XORTX's mission is to mitigate the effects of aberrant purine metabolism and high uric acid levels, developing medications that improve patients' health.
Connecting with XORTX
For further inquiries or more information about XORTX’s innovative drug development, interested parties can contact:
Allen Davidoff, CEO
+1 403 455 7727
adavidoff@xortx.com
Nick Rigopulos, Director of Communications
+1 617 901 0785
nick@alpineequityadv.com
Frequently Asked Questions
What is the primary purpose of the funds raised by XORTX?
The funds are primarily intended to support the company's gout programs and general corporate needs.
How many units were issued in the private placement?
A total of 156,849 units were issued at a price of USD $0.73 per unit.
What can warrant holders do with their warrants?
Holders can purchase additional common shares at USD $1.20 per share for a period of 60 months following issuance.
Is the offering subject to any restrictions?
Yes, the securities are subject to a statutory hold period of four months and one day, as per regulatory compliance.
What innovative therapies does XORTX Therapeutics offer?
XORTX is developing therapies for gout, ADPKD, acute kidney injuries, and Type 2 diabetic nephropathy.
